INTRODUCTION
Glycosaminoglycans (GAGs), as major components of the extracellular matrix, are essential for the structure and function of connective tissues. The different GAG compounds [hyaluronic acid (HA), chondroitin-0, 4-and 6-sulphate, dermatan sulphate (DS), heparan sulphate and keratan sulphate] represent a structurally heterogeneous group of polyanionic, linear polysaccharides composed mainly of repeating disaccharide units comprising substituted D-uronic or L-iduronic acid and D-glucosamine or D-galactosamine residues. In contrast to HA, the remaining extracellular GAG components are bound to structural proteins to form proteoglycans. All GAGs except HA are polysulphated, which, together with multiple carboxyl residues, leads to a strong polyanionic charge and hydrophilia [l] . After synthesis in fibroblasts and related cells the abundant majority of GAGs are released into the extracellular matrix. The macromolecules are subjected to permanent catabolism. Peptide-bound GAGs are immediately eliminated from circulation by uptake into endothelial and hepatic cells, where they undergo further intracellular degradation. Only free GAG chains are encountered in considerable amounts in the blood, from where they are renally eliminated [2] . The biological functions of GAGs include an important role in the regulation of cell proliferation and differentiation, cell-to-matrix binding, regulation of diffusion of macromolecules through tissues, growth-factor attachment, cellto-cell interaction and regulation of interleukin-1 production in local inflammatory response [3-51. The pathogenic changes in patients with Graves' ophthalmopathy (GO) evolve, via retrobulbar oedema, to the clinical manifestation of exophthalmos [6-81. Although there is strong evidence of an involvement of connective tissue in GO, together with massive accumulation of GAG and infiltration of immunocompetent cells into orbital connective tissue as well as into the interstitium of extraocular muscles [9-111, the actual nature of this autoimmune process has up to now remained enigmatic. It has been shown that interleukin-1, produced by macrophages and fibroblasts within the orbit of G O patients, stimulates GAG synthesis by orbital fibroblasts [12, 131 . Consequently, a test system to determine the amount of free GAG-degradation products measurable in patients' urine samples, which may reflect the aberrant GAG synthesis and metabolism and hence the activity of the underlying orbital disease, has been sought. The methods currently available for determination of GAG components in biological fluids tend to be lengthy and complicated, and are subject to various limitations. The most common techniques are the measurement of overall GAG content by photometrical quantification of uronic acids [14, 151, ion-exchange chromatography [16] and gel electrophoresis, followed by quantification by densitometry [17] . In the present study, a specific HPLC method was applied to determine the concentration and biochemical composition of GAG and different GAG components in the urine of G O patients in comparison with controls, and compared with the classical techniques.
MATERIAL AND METHODS

Patients
GAG excretion in 24 h urine collections (stored deep-frozen at -20°C) was determined in 56 G O patients and 21 healthy controls (Table 1) . A complete clinical investigation, including an ophthalmological and endocrinological check-up, was performed in all G O patients. The presence of bladder and kidney diseases were excluded. Informed consent was obtained from patients and controls where appropriate and the reported investigations have been approved by the responsible ethical committee. Forty-two patients had active Graves' eye disease (score > 5 out of 7 points for conjunctival injection, chemosis, eyelid erythema and oedema and spontaneous pain, as well as on ocular movements), according to the recently published classification of eye changes in Graves' disease and recommendations of the joint committees of the world thyroid associations [18] and the proposed clinical activity score of Mourits et al. [19] . Patients with inactive disease had a score of less than 3 points. Thirty-one G O patients had no immunosuppressive treatment, whereas 22 patients with active eye disease were treated with steroids (prednisone, starting dose 50mg/day). Of these 22 patients, 6 were receiving additional retrobulbar 
Quantitative analysis of urinary GAGs
GAGs were isolated from 15 mi of the well-mixed 24 h urine collections in duplicate after separation of insoluble constituents by centrifugation (2000 g, 10 min, room temperature) by a modified two-step precipitation procedure [20] . In brief, 10ml of the supernatant was incubated with 0.4 ml of 0.28 moll1 aqueous cetylpyridinium chloride (Merck, Darmstadt, Germany; 20 h at 4°C). After centrifugation (3200 g, 40 min, 4"C), the precipitate was suspended in 10ml of 0.1 mol/l potassium acetate in 99.5% ethanol (Merck; 12h, 4°C). Quantification of the GAG raw product, obtained as a precipitate after centrifugation (3200 g, 35 min, 4"C), was performed by a classical colorimetric test with carbazole [21] . In a boiling-water bath an aliquot of each sample (0.2 ml, dissolved in HPLC-grade water) was incubated for 10 min with 0.09 ml of 7.5 mmol/l carbazole in 95% ethanol (Merck), in the presence of 0.9 ml of borate/sulphuric acid (25 mmol/l sodium tetraborate decahydrate in concentrated sulphuric acid; Merck), leading to a pinkish stain of uronic acids. After cooling to room temperature for 30 min, the absorbance of the solution was measured at 530 nm, followed by determination of the GAG concentration, expressed as mg/24 h uronic acid, by reference to a standard calibration curve of D-glucurono-y-lactone (Merck; 0-140 mg/l). Coefficients of variation for intra-and inter-assay were <5 and 7.5 respectively (n = 10).
Qualitative analysis
The different GAG components were analysed in duplicate by sequential enzymic hydrolysis with chondroitin AC lyase and chondroitin ABC lyase as well as hyaluronate lyase, with anion-exchange HPLC analysis of the resulting a,/?-unsaturated disaccharides, based on methods described previously [22-241. Furthermore, in order to compare the combined method of specific enzyme digestion and HPLC analysis with the commonly used classical dye reaction with carbazole [21] , all urine samples were analysed by both methods in duplicate. For the first enzymic digestion step, 10 pl of chondroitin AC lyase (EC 4.2.2.5, from Arthrobacter aurescens; Sigma, Germany; 2.5 units/ml in HPLC-grade water) was mixed with an aqueous solution of GAG containing 10 pg of uronic acid in 10-50 p1 and sodium dihydrogenphosphate buffer (50 mmol/l, pH 7.9) in a final volume of 200p1, followed by incubation at 36°C for 4 h. The incubation step was repeated after addition of another lop1 of chondroitin AC lyase solution under the same conditions. An external standard of 1Opg of chondroitin sulphate A (CA) (from bovine trachea; Sigma; 10 p1, 1 g/l in HPLCgrade water) in 200pl of sodium dihydrogenphosphate buffer, treated under the same conditions, was employed in every digestion reaction. Each enzymic digestion step was stopped by dipping the probes into a boiling-water bath for 30 s, causing degradation of the digestion enzyme, followed by separation of the disaccharide products from undigested GAG by precipitation of the undigested material with 4 ml of 99.5% HPLC-grade ethanol (12h, 4°C) and centrifugation (3200 g, 10 min, 4°C). In the supernatant the solvent was removed by evaporation and the residue was dissolved in 0.12 ml of HPLC-grade water, followed by centrifugation (15 000 g, 20 min, room temperature) and HPLC analysis of 0.04ml aliquots of the resulting solution, while the sediment was subjected to the next digestion step. For the second degradation the sediment was dissolved in 200 pl of 50 mmol/l sodium dihydrogenphosphate buffer, pH 7.9, and 20 pl of chondroitin ABC lyase (EC 4.2.2.4 from Proteus vulgaris; Sigma; 2.5 units/ ml in HPLC-grade water) was added (36"C, 4 h).
Incubation was repeated after addition of another 20 p1 of chondroitin ABC lyase solution under the same conditions. As an external standard 1Opg of DS (from bovine mucosa; Sigma; 1Op1, 1 g/l in HPLC-grade water) in 200 pl of sodium dihydrogenphosphate buffer, was employed. Subsequently, the samples were prepared for HPLC analysis and the next incubation step, as mentioned above. For the third degradation the ethanol sediment 'was dissolved in 20Opl of 50mmol/l sodium dihydrogenphosphate buffer, pH6.0, mixed with 4Opl of hyaluronidase (EC 4.2.2.1, from Streptomyces hyalurolyticus; Merck; 60 World Health Organization unitdm1 in 20 mmol/l sodium dihydrogenphosphate/ 0.45% NaCl/O.Ol% BSA, pH6.0) and incubated at 60°C for 4 h. Incubation was repeated after addition of another 40 p1 of hyaluronidase under the same conditions. As external standard 10 pg of HA (from umbilical cord; Sigma; 10 pl, 1 g/l in HPLC-grade water) was used. After ethanol precipitation of the undigested compounds, the supernatants, containing the disaccharide degradation products, and the sediments were prepared for HPLC analysis as mentioned before.
HPLC analysis
Quantification was achieved by analysis of the a,/?-unsaturated disaccharide degradation products by anion-exchange HPLC. Chromatography was performed by means of a concave sodium phosphate gradient (100-750 mmol/l) on a Bio-Sil amino 5s disaccharide column consisting of aminopropyl residues as functional groups bound to a silica matrix. The chromatographic system was comprised of the following modules: Waters 625 LC inert system (dynamic flow rate 0.01-5 ml/min; Waters, Eschborn, Germany), DG 2410 degas unit (VDS optilab, Berlin, Germany), Waters 717 autosampler (injection volume 1-2000 p1, 48-vial carousel, Peltier temperature module 4-40°C), Waters 996 photodiode-array detector (UVNIS, 190-800 nm), Waters Millennium 2010 chromatography manager software and Bio-Sil amino 5s disaccharide columns (250 x 4 mm, aminopropyl groups bound to bonded silica, particle size 5 pm, pore size 8 nm; Bio-Rad, Munich, Germany). The columns were protected by using Bio-Sil amino 5s micro-guard precolumns (30 x 4.6 mm; Bio-Rad, Germany) in a Micro-guard cartridge holder (Bio-Rad). The precolumn cartridges were exchanged after approximately 100-150 runs. The injection volume was lop1 for reference kit injections and 40 pl for sample injections. Elution was performed with a concave gradient of 100-750 mmol/l sodium dihydrogenphosphate buffer, pH 4.0, filtered through a 0.2 pm celluloseacetate filter (Sartorius, Goettingen, Germany) and de-gassed with the on-line de-gassing unit at room temperature. The absorbance of the eluate was detected at 200-300 nm and the chromatogram was recorded at a wavelength of 230 nm. Quantification was performed by calibration with a reference kit of the pure CA, DS and HA disaccharides (Medac, Hamburg, Germany), and by comparison with the digestion products of the external standards of the pure GAG components CA, DS and HA at every run. The retention time of the degradation products was confirmed by addition of the corresponding pure disaccharides to the samples. For each enzymic digestion reaction, sodium dihydrogenphosphate buffer, pH7.0, was submitted to the same degradation procedure and analysed as control. Coefficients of variation for intra-and inter-assay were c2 and 3.5 respectively (n = 10). The linear range of the method was 0.02-500 pmol/l.
Statistical analysis
Distribution of urinary GAG levels is presented as the mean values f SEM. Differences between GAG excretion of different subgroups were evaluated by means of the two-sample Wilcoxon test; P < 0.05 was considered significant.
RESULTS
HPLC application
Typical chromatograms representing the GAG excretion pattern of patients and controls obtained by HPLC analysis of the digestion products are shown in Figs. l(a) and l(b) , in comparison with the digestion pattern of standard solutions of CA (Fig.lc) , DS and HA (Fig.ld) . Absorption signals were analysed according to the UV spectra of the corresponding disaccharides (absorption maximum at 230nm). The detector response was linear from 0.02 to 500 pmol/l with a detection limit for HPLC analysis of 0.01 pmol/l (signal-to-noise ratio of 4).
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The urine samples of patients and controls showed well-defined chromatograms with seven disaccharide signals in specimens of patients [ Table 2 Coefficients of variation for intra-and inter-assay were < 2 and <3.5 respectively (GAG concentrations 0.02 and 500 pmol/l, n = 10, respectively) for the combined enzymic digestion and HPLC-analysis. In contrast, the coefficients of variation of the classical carbazole test ranged from 2.9 (GAG concentra- In contrast to the classical dye reaction with carbazole, the combination of specific enzyme digestion and HPLC analysis showed higher recovery rates which differ depending on the GAG compounds employed (44% higher for CA, 29.3% for DS and 27.0% for HA respectively).
-acetam~do-2-deoxy-3-O-~-~-gluco~4~enepyranosyluron~c acid)-4-0-sulpho-D-galactose (Di-HA), 6.88 min] and DS [2-acetamido-2-deoxy-3~O-(2-O-sulpho-~-~-gluco-4-enepy~nosyluronic acid)-D-galactose (Di-UA2S) 14.37 min; D i 4 ,
min; 2-acetam~do-2-deoxy-3-O-(2-O-sulpho-~-~-gluco-4-enepy~no~luronic acid)-4-0-sulpho-~-galactose
Clinical findings
A combination of enzymic digestion and HPLC analysis showed an overall GAG excretion ranging Table 3) . CA concentration was also elevated. Comparing the subgroups, total GAG content was elevated in active and untreated patients in contrast to patients with inactive or treated eye disease. With respect to urinary CA excretion, the most pronounced increase was also observed in patients with active and untreated GO. Solely, DS excretion from patients with active GO exhibited a significant increase in comparison with patients with inactive disease. HA increase was most pronounced in 42 patients with active GO and 31 untreated patients. In comparison with controls, the GAG distribution pattern was changed in GO patients and was apparent in a decrease in urinary CA excretion (from 59.6% of total GAG excretion measured by HPLC analysis in controls to 46.0% in patients) and a simultaneous increase of DS (con- 
DISCUSSION
Based on previous investigations, which strongly suggested an association of elevated GAGS in body fluids with the presence of GO , it was our endeavour to search for a reliable HPLC method which would accurately measure the concentration of total GAG and different GAG components (CA, DS and HA) in order to enable diagnosis and evaluation of disease activity and success of therapy. To our knowledge, the different GAG compounds have been analysed for the first time in urine samples of GO patients by a combination of enzymic digestion and HPLC analysis of the resulting degradation products. By means of the present method, total GAG concentration and structural information about disaccharide composition, degree of sulphation and proportion of 0-sulphated, 4-sulphated and 6-sulphated isomers can be determined. This is achieved by sequential application of the substratespecific enzymes chondroitin AC lyase for the diges- tion of chondroitin A and C, chondroitin ABC lyase for the degradation of DS, and hyaluronate lyase for the reaction with HA. Separation of the digestion products from undigested GAG by ethanol precipitation of the undigested compounds after each digestion step permits the determination of GAG distribution patterns. The method represents a reliable test system for the detection and quantification of GAG components, with overall recovery rates and sensitivities which are superior to other methods used in the past, such as colorimetric tests and paper, thin-layer, liquid or gas chromatography, gel electrophoresis and radiometric assays [14-17, 28-31]. A further advantage of the HPLC method is the possibility for automation and its high reproducibility. Furthermore, structural modifications of all GAG components, which may reflect pathological alterations, can be directly examined by means of the disaccharide HPLC-elution pattern.
One major problem still exists in the procedure of sample preparation. Although cetylpyridinium chloride precipitation has been optimized, with recovery rates of > 90% (GAG concentration 20.1 mg/ml and addition of carrier substances at lower concentrations), it is nevertheless a time-consuming step. But pre-purification of human bodyfluid samples, like urine and serum, by precolumn treatment, bears the disadvantage of high recovery losses of the highly negatively charged molecules, especially at low GAG concentrations.
Regarding the sequence of application of the GAG lyases, recovery rates using the order employed in the present study proved to be superior to other methods that used hyaluronate lyase digestion as the first degradation step [23] , since CA and DS can also be digested by hyaluronate lyase [24] . Comparison of the specific-enzyme digestion and HPLC analysis method with the commonly used dye reaction showed the higher recovery rate, sensitivity and reproducibility of the HPLC analysis. Furthermore, using the carbazole test, only the uronic acid content can be determined, which is only 50% of the disaccharide units and is absent in keratan sulphate. This is a fact that leads to markedly lower concentration values and considerable discrepancies in the assessment of different GAG compounds. In cases where the distribution pattern of GAG components has to be analysed, a more selective method than the carbazole test must be used.
Enzymic digestion and HPLC analysis of GAG compounds has been successfully applied in human articular cartilage [23] and in serum and plasma samples [24] using different chromatographic columns, such as strong anion-exchange and reversedphase columns. In this study we employed an aminopropyl column which is designed for disaccharide separation based on polar and hydrophobic interactions dependent upon the mobile phase used. By means of this column it is possible to separate uncharged, low-charged and high-charged disaccharide units in parallel, so that non-sulphated HA disaccharides as well as the low-charged monosulphated 0-, 4-and 6-isomers of CA and the highcharged polysulphated disaccharides of CA and DS can be separated and the absolute concentration of the different GAG compounds can be determined. It has been reported that the absolute value of plasma GAG concentration appears to be dependent on physical training and age of the subjects [32, 331. However, in our GO patients and control groups neither total GAG content nor the concentration of different GAG compounds exhibited any correlation with age, sex or physical training of the persons examined.
In the present study, results of the urinary disaccharide analysis show a marked increase in total GAG as well as CA, DS and HA concentrations in GO patients in comparison with healthy controls. The advantage of using the HPLC method is that a comprehensive analysis of the disaccharide composition of various GAG components can be made, revealing any differences in their structure and hence their properties. The major portion of the elevated GAG is represented by CA, which can be related to the findings in normal urine samples where low-molecular-mass CA and heparan sulphate are the major urinary GAG compounds [34] . DS and HA, which are detected in low concentrations in urinary samples of GO patients and controls, are elevated too. With regard to subgroups of patients, the most pronounced differences for all three GAG compounds examined were found between patients with active and inactive Graves' eye disease. These findings cannot be achieved by the classical colorimetric tests which only measure the overall GAG concentrations in uronic acid equivalents [21] .
In conclusion, urinary GAG determinations can be applied to analyse connective tissue changes in patients with Graves' disease. Insights into the exact mechanisms. by which these components participate in the pathogenesis of extra-thyroidal manifestations of this disease will have to be gained in further studies.
